Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bazlitoran - Aceragen

Drug Profile

Bazlitoran - Aceragen

Alternative Names: Bazlitoran-sodium; IMO-8400

Latest Information Update: 20 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Idera Pharmaceuticals
  • Developer Aceragen
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antisense oligonucleotides; Immunotherapies
  • Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists; Toll-like receptor 9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Diffuse large B cell lymphoma; Waldenstrom's macroglobulinaemia
  • No development reported Graft-versus-host disease; Systemic lupus erythematosus
  • Discontinued Dermatomyositis; Duchenne muscular dystrophy; Plaque psoriasis

Most Recent Events

  • 17 Jan 2023 Idera Pharmaceuticals is now called Aceragen
  • 15 Mar 2022 Idera Pharmaceuticals has chemical composition of matter patent protection for bazlitoran in US
  • 08 Nov 2019 Efficacy and safety data from a phase II trial in Dermatomyositis presented at the 83rd American College of Rheumatology and the 54th Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top